Dataset Information

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

ABSTRACT:

Background

Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations.

Objective

To report the first year's screening results for all men at enrollment in the study.

Design, setting and participants

We recruited men aged 40-69 yr with germline BRCA1/2 mutations and a control group of men who have tested negative for a pathogenic BRCA1 or BRCA2 mutation known to be present in their families. All men underwent prostate-specific antigen (PSA) testing at enrollment, and those men with PSA >3 ng/ml were offered prostate biopsy.

Outcome measurements and statistical analysis

PSA levels, PCa incidence, and tumour characteristics were evaluated. The Fisher exact test was used to compare the number of PCa cases among groups and the differences among disease types.

Results and limitations

We recruited 2481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls). A total of 199 men (8%) presented with PSA >3.0 ng/ml, 162 biopsies were performed, and 59 PCas were diagnosed (18 BRCA1 carriers, 10 BRCA1 controls; 24 BRCA2 carriers, 7 BRCA2 controls); 66% of the tumours were classified as intermediate- or high-risk disease. The positive predictive value (PPV) for biopsy using a PSA threshold of 3.0 ng/ml in BRCA2 mutation carriers was 48%-double the PPV reported in population screening studies. A significant difference in detecting intermediate- or high-risk disease was observed in BRCA2 carriers. Ninety-five percent of the men were white, thus the results cannot be generalised to all ethnic groups.

Conclusions

The IMPACT screening network will be useful for targeted PCa screening studies in men with germline genetic risk variants as they are discovered. These preliminary results support the use of targeted PSA screening based on BRCA genotype and show that this screening yields a high proportion of aggressive disease.

Patient summary

In this report, we demonstrate that germline genetic markers can be used to identify men at higher risk of prostate cancer. Targeting screening at these men resulted in the identification of tumours that were more likely to require treatment.

SUBMITTER: Bancroft EK

PROVIDER: S-EPMC4105321 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Bancroft Elizabeth K EK Page Elizabeth C EC Castro Elena E Lilja Hans H Vickers Andrew A Sjoberg Daniel D Assel Melissa M Foster Christopher S CS Mitchell Gillian G Drew Kate K Mæhle Lovise L Axcrona Karol K Evans D Gareth DG Bulman Barbara B Eccles Diana D McBride Donna D van Asperen Christi C Vasen Hans H Kiemeney Lambertus A LA Ringelberg Janneke J Cybulski Cezary C Wokolorczyk Dominika D Selkirk Christina C Hulick Peter J PJ Bojesen Anders A Skytte Anne-Bine AB Lam Jimmy J Taylor Louise L Oldenburg Rogier R Cremers Ruben R Verhaegh Gerald G van Zelst-Stams Wendy A WA Oosterwijk Jan C JC Blanco Ignacio I Salinas Monica M Cook Jackie J Rosario Derek J DJ Buys Saundra S Conner Tom T Ausems Margreet G MG Ong Kai-ren KR Hoffman Jonathan J Domchek Susan S Powers Jacquelyn J Teixeira Manuel R MR Maia Sofia S Foulkes William D WD Taherian Nassim N Ruijs Marielle M Helderman-van den Enden Apollonia T AT Izatt Louise L Davidson Rosemarie R Adank Muriel A MA Walker Lisa L Schmutzler Rita R Tucker Kathy K Kirk Judy J Hodgson Shirley S Harris Marion M Douglas Fiona F Lindeman Geoffrey J GJ Zgajnar Janez J Tischkowitz Marc M Clowes Virginia E VE Susman Rachel R Ramón y Cajal Teresa T Patcher Nicholas N Gadea Neus N Spigelman Allan A van Os Theo T Liljegren Annelie A Side Lucy L Brewer Carole C Brady Angela F AF Donaldson Alan A Stefansdottir Vigdis V Friedman Eitan E Chen-Shtoyerman Rakefet R Amor David J DJ Copakova Lucia L Barwell Julian J Giri Veda N VN Murthy Vedang V Nicolai Nicola N Teo Soo-Hwang SH Greenhalgh Lynn L Strom Sara S Henderson Alex A McGrath John J Gallagher David D Aaronson Neil N Ardern-Jones Audrey A Bangma Chris C Dearnaley David D Costello Philandra P Eyfjord Jorunn J Rothwell Jeanette J Falconer Alison A Gronberg Henrik H Hamdy Freddie C FC Johannsson Oskar O Khoo Vincent V Kote-Jarai Zsofia Z Lubinski Jan J Axcrona Ulrika U Melia Jane J McKinley Joanne J Mitra Anita V AV Moynihan Clare C Rennert Gad G Suri Mohnish M Wilson Penny P Killick Emma E Moss Sue S Eeles Rosalind A RA

European urology 20140115 3

<h4>Background</h4>Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations.<h4>Objective</h4>To ...[more]

PMID: 24484606

Similar Datasets

Project description:BackgroundMutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.ObjectiveTo report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3?yr of screening, by BRCA status.Design, setting, and participantsMen aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3?yr, and if PSA?>?3.0?ng/ml, men were offered prostate biopsy.Outcome measurements and statistical analysisPSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians.Results and limitationsA total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3?yr of screening, 527 men had PSA?>?3.0?ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p?=? 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64?yr; p?=? 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p?=? 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC]?=?0.73) for clinically significant cancer at biopsy than PSA alone (AUC?=?0.65).ConclusionsAfter 3?yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers.Patient summaryWe demonstrate that after 3?yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.

Project description:BACKGROUND:BRCA1 and BRCA2 mutations have been associated with prostate cancer (PCa) risk but a wide range of risk estimates have been reported that are based on retrospective studies. OBJECTIVE:To estimate relative and absolute PCa risks associated with BRCA1/2 mutations and to assess risk modification by age, family history, and mutation location. DESIGN, SETTING, AND PARTICIPANTS:This was a prospective cohort study of male BRCA1 (n = 376) and BRCA2 carriers (n = 447) identified in clinical genetics centres in the UK and Ireland (median follow-up 5.9 and 5.3?yr, respectively). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:Standardised incidence/mortality ratios (SIRs/SMRs) relative to population incidences or mortality rates, absolute risks, and hazard ratios (HRs) were estimated using cohort and survival analysis methods. RESULTS AND LIMITATIONS:Sixteen BRCA1 and 26 BRCA2 carriers were diagnosed with PCa during follow-up. BRCA2 carriers had an SIR of 4.45 (95% confidence interval [CI] 2.99-6.61) and absolute PCa risk of 27% (95% CI 17-41%) and 60% (95% CI 43-78%) by ages 75 and 85?yr, respectively. For BRCA1 carriers, the overall SIR was 2.35 (95% CI 1.43-3.88); the corresponding SIR at age <65?yr was 3.57 (95% CI 1.68-7.58). However, the BRCA1 SIR varied between 0.74 and 2.83 in sensitivity analyses to assess potential screening effects. PCa risk for BRCA2 carriers increased with family history (HR per affected relative 1.68, 95% CI 0.99-2.85). BRCA2 mutations in the region bounded by positions c.2831 and c.6401 were associated with an SIR of 2.46 (95% CI 1.07-5.64) compared to population incidences, corresponding to lower PCa risk (HR 0.37, 95% CI 0.14-0.96) than for mutations outside the region. BRCA2 carriers had a stronger association with Gleason score ?7 (SIR 5.07, 95% CI 3.20-8.02) than Gleason score ?6 PCa (SIR 3.03, 95% CI 1.24-7.44), and a higher risk of death from PCa (SMR 3.85, 95% CI 1.44-10.3). Limitations include potential screening effects for these known mutation carriers; however, the BRCA2 results were robust to multiple sensitivity analyses. CONCLUSIONS:The results substantiate PCa risk patterns indicated by retrospective analyses for BRCA2 carriers, including further evidence of association with aggressive PCa, and give some support for a weaker association in BRCA1 carriers. PATIENT SUMMARY:In this study we followed unaffected men known to carry mutations in the BRCA1 and BRCA2 genes to investigate whether they are at higher risk of developing prostate cancer compared to the general population. We found that carriers of BRCA2 mutations have a high risk of developing prostate cancer, particularly more aggressive prostate cancer, and that this risk varies by family history of prostate cancer and the location of the mutation within the gene.

Dataset Information

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Background

Objective

Design, setting and participants

Outcome measurements and statistical analysis

Results and limitations

Conclusions

Patient summary

Publications

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets